Bart Filius
CIK: 0002115417
Transaction Breakdown
Open Market Buys (P)1 (100.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
PRQR
ProQR Therapeutics N.V.
Director
Discretionary Trading P&L
Holdings
About Filius Bart
Filius Bart (SEC CIK 0002115417) files insider reports with the SEC as Director of ProQR Therapeutics N.V. (PRQR).
Signal8 holds 2 ownership filings by Filius Bart (1 Form 3, 1 Form 4), filed between Mar 18, 2026 and Jul 21, 2026. Those filings report 1 transaction, the latest on Jul 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Filius Bart's filings is in LEIDEN.
Recent filings by Filius Bart
- Jul 17, 2026: Open-market purchase of PRQR shares (Form 4, code P).
Other insiders filing for ProQR Therapeutics N.V. (PRQR)
- de Boer Daniel Anton, Chief Executive Officer
- Hinsch Gylvin Lykke, Director
- Valerio Domenico, Director
- Platenburg Gerardus Johannes, Chief Scientific Officer
- Maier Martin Alexander, Director
- Lawton Alison Frances, Director